331 related articles for article (PubMed ID: 15094442)
21. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
[TBL] [Abstract][Full Text] [Related]
22. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
23. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
24. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
Fallahi B; Beiki D; Takavar A; Fard-Esfahani A; Gilani KA; Saghari M; Eftekhari M
Nucl Med Commun; 2012 Mar; 33(3):275-82. PubMed ID: 22124360
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
26. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
28. Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?
Dietlein M; Luyken WA; Schicha H; Larena-Avellaneda A
Nucl Med Commun; 2005 Jan; 26(1):3-8. PubMed ID: 15604941
[TBL] [Abstract][Full Text] [Related]
29. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
30. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
Hodgson DC; Brierley JD; Tsang RW; Panzarella T
Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing radioiodine uptake after thyroid cancer surgery.
Bai JB; Shakerian R; Westcott JD; Lichtenstein M; Miller JA
ANZ J Surg; 2015; 85(7-8):572-7. PubMed ID: 23964714
[TBL] [Abstract][Full Text] [Related]
32. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
Bajén MT; Mañé S; Muñoz A; García JR
J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
[TBL] [Abstract][Full Text] [Related]
33. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
34. Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma.
Arslan N; Ilgan S; Serdengecti M; Ozguven MA; Bayhan H; Okuyucu K; Gulec SA
Nucl Med Commun; 2001 Sep; 22(9):1021-7. PubMed ID: 11505212
[TBL] [Abstract][Full Text] [Related]
35. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.
Verkooijen RB; Stokkel MP; Smit JW; Pauwels EK
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):499-506. PubMed ID: 14722676
[TBL] [Abstract][Full Text] [Related]
37. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
[TBL] [Abstract][Full Text] [Related]
38. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
39. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I.
Verburg FA; Verkooijen RB; Stokkel MP; van Isselt JW
Nuklearmedizin; 2009; 48(4):138-42; quiz N19-20. PubMed ID: 19384451
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]